Literature DB >> 10208287

A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder.

Y Sasson1, I Iancu, M Fux, M Taub, P N Dannon, J Zohar.   

Abstract

OBJECTIVE: To compare the efficacy of clomipramine hydrochloride (CMI), a serotonin reuptake inhibitor with the noradrenergic tricyclic antidepressant agent, and desipramine hydrochloride (DMI) for patients with panic disorder (PD).
METHOD: Following a 2-week, single-blind placebo washout phase, 17 PD outpatients completed a 16-week, double-blind, crossover comparison of CMI and DMI. Key outcome measures included panic attacks frequency, the NIMH Global Scales for Anxiety, Depression and Impairment, Hamilton Anxiety Scale (Psychic and Somatic Subscales), Zung Anxiety Inventory (Raw and Index Subscales) and the Spielberger State Anxiety Scale.
RESULTS: Both CMI and DMI led to significant improvement from baseline placebo state in panic attacks frequency and behavioral ratings (p<0.001). CMI led to a greater reduction in the frequency of panic attacks (p=0.028) and was superior to DMI on ratings of anxiety: NIMH Global Anxiety, Zung Anxiety Scale (Raw and Index) and the Spielberger Anxiety Scale. No difference was found between the drugs on the NIMH Global Impairment Scale and the Hamilton Somatic and Psychic Scales.
CONCLUSION: Both drugs appeared to have significant therapeutic effects in patients with PD, but CMI appeared to be more effective. The effectiveness of the serotonergic drug suggests that the role of the serotonergic system in the pathogenesis of PD should be further explored.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208287     DOI: 10.1016/s0924-977x(98)00024-8

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  7 in total

Review 1.  Panic disorder.

Authors:  M H Rapaport; C Barrett
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

2.  Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect.

Authors:  Shinji Miyata; Takashi Hamamura; Youmei Lee; Masahito Miki; Toshiaki Habara; Takuro Oka; Shiro Endo; Hideki Taoka; Shigetoshi Kuroda
Journal:  Psychopharmacology (Berl)       Date:  2004-11-17       Impact factor: 4.530

3.  Exposure to violence and its relationship to psychopathology in adolescents.

Authors:  C L Ward; A J Flisher; C Zissis; M Muller; C Lombard
Journal:  Inj Prev       Date:  2001-12       Impact factor: 2.399

4.  Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.

Authors:  Andrew J Melaragno
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-06-17

5.  A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

Authors:  Mark Pollack; Richard Mangano; Richard Entsuah; Evan Tzanis; Naomi M Simon; Ying Zhang
Journal:  Psychopharmacology (Berl)       Date:  2007-06-23       Impact factor: 4.530

Review 6.  Diagnosis and treatment of agoraphobia with panic disorder.

Authors:  Giulio Perugi; Franco Frare; Cristina Toni
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  The noradrenergic paradox: implications in the management of depression and anxiety.

Authors:  Alonso Montoya; Robert Bruins; Martin A Katzman; Pierre Blier
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-01       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.